EPARs - Extavia//interferon beta-1b

FICHA FARMACOLÓGICA de interferon beta-1b. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. ABRIL 18, 2009.-

abrir aquí:
EPARs for authorised medicinal products for human use - Extavia

Active Substance
interferon beta-1b
International Nonproprietary Name or Common Name
interferon beta-1b
Pharmaco-therapeutic Group
Interferons
ATC Code
L03AB08

Therapeutic Indication:
Extavia is indicated for the treatment of:
- Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
- Patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years.

- Patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.

Date of issue of Marketing Authorisation valid throughout the European Union
20 May 2008